Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
aptamer |
| gptkbp:approvalYear |
2004
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
S01LA03
|
| gptkbp:brand |
gptkb:Macugen
|
| gptkbp:CASNumber |
320345-99-1
|
| gptkbp:developer |
gptkb:Pfizer
gptkb:Eyetech_Pharmaceuticals |
| gptkbp:eliminationHalfLife |
10 days (in vitreous)
|
| gptkbp:hasMolecularFormula |
C294H374F2N113Na39O190P39
|
| https://www.w3.org/2000/01/rdf-schema#label |
pegaptanib
|
| gptkbp:KEGGID |
D04733
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
VEGF inhibitor
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:PubChem_CID |
16130129
CHEMBL1201832 DB00082 |
| gptkbp:routeOfAdministration |
intravitreal injection
|
| gptkbp:sideEffect |
inflammation
eye pain increased intraocular pressure floaters |
| gptkbp:synonym |
EYE001
|
| gptkbp:target |
VEGF165 isoform
|
| gptkbp:UNII |
Q1U8A8V977
|
| gptkbp:usedFor |
age-related macular degeneration
|
| gptkbp:bfsParent |
gptkb:vascular_endothelial_growth_factor_A
|
| gptkbp:bfsLayer |
6
|